Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 8/20 | 0.43 |
| ▸ | NPY1R | P25929 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7965101 | 0.82 | CRHR1 (0.56) | CRHR1KMT2A | |
| SCHEMBL6053303 | 0.81 | CRHR1 (0.52) | CRHR1NPY1RTP53KDM4EALDH1A1 | |
| SCHEMBL7628525 | 0.72 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL7641907 | 0.70 | CRHR1 (0.50) | CRHR1TP53KDM4EALDH1A1HPGD | |
| SCHEMBL7628534 | 0.70 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL7916250 | 0.70 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5786582 | 0.66 | NPY1R (0.55) | CRHR1NPY1RHPGD | |
| SCHEMBL5599498 | 0.65 | CRHR1 (0.72) | CRHR1 | |
| SCHEMBL5845875 | 0.65 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5599495 | 0.64 | CRHR1 (0.50) | CRHR1NPY1RKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156089-A1 | Use of CRF antagonists and related compositions | PFIZER INC. | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156089-A1 | Use of CRF antagonists and related compositions | CRH, CRHR1, CRHR2 | CRHR1 2/4885NPY1R 82/4885TLR8 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.